Posts by Luke

WHO and Africa CDC launched a six-month Ebola response plan seeking $518 million for surveillance, labs, care, logistics, and community trust.

Reuters says the FDA has launched a safety study of mifepristone, a review that could become the basis for new restrictions.

The FDA’s first step toward qualifying an AI liver-toxicity model is promising, but the real test is whether faster drug development strengthens trust or just shifts risk.

Acting FDA Commissioner Kyle Diamantas met rare-disease groups after recent regulatory clashes, showing that predictability has become a core public-health asset.

Reuters reports more than two dozen ASCO studies found cancer-related benefits associated with GLP-1 drugs, but most evidence remains observational — exactly where public trust can be built or burned.

The FDA’s draft guidance for using existing science in rare-disease gene therapy could speed development, but only if public trust and safety review keep pace.

Reuters reported Tuesday that the U.S. Food and Drug Administration declined to approve Cingulate’s ADHD drug. The decision is a narrow regulatory event, but it belongs in a wider public-trust story. ADHD treatment sits at the intersection of families, schools, physicians, insure

A planned U.S.-backed Ebola quarantine facility in Kenya triggered protests and a court pause, exposing the trust deficit behind cross-border public-health logistics.

A new FDA approval for Shionogi’s COVID-prevention pill lands in a public-health environment where implementation trust matters as much as scientific clearance.

Promising pancreatic cancer drug data is a hopeful story, but it also exposes the public-trust problem inside a healthcare system where access, evidence, and bureaucracy move at different speeds.